We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Generation of Antibiotics Disrupts Quorum Sensing

By LabMedica International staff writers
Posted on 24 Mar 2009
Drug developers are working on a new generation of antibiotics that do not kill bacteria but instead disrupt the communication system known as "quorum sensing,” which induces the microorganisms to manufacture disease-causing toxins.

Several types of bacteria, including such human pathogens as Vibrio cholerae and Escherichia coli O157:H7, can grow within a host without harming it, until they reach a certain concentration. More...
They become aggressive when their numbers become sufficient to overcome the host's immune system and form a biofilm, leading to disease. The language of quorum sensing is based on the bacterial population producing and detecting signaling molecules known as autoinducers.

Investigators from the Albert Einstein College of Medicine (New York, NY, USA) focused on the bacterial enzyme 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase (MTAN), which is involved in S-adenosylmethionine–related quorum sensing pathways that induce bacterial pathogenesis factors. To block MTAN activity they created a series of transition state analogs, MT-DADMe-Immucillin-A, EtT-DADMe-Immucillin-A, and BuT-DADMe-Immucillin-A, which are slow-onset, tight-binding inhibitors of V. cholerae MTAN (VcMTAN).

Results published in the March 8, 2009, online edition of the journal Nature Chemical Biology revealed that in V. cholerae cells, the compounds were potent MTAN inhibitors. Structural analysis of VcMTAN with BuT-DADMe-Immucillin-A revealed interactions contributing to the high affinity. The compounds disrupted autoinducer production in a dose-dependent manner without affecting growth. MT- and BuT-DADMe-Immucillin-A also inhibited autoinducer-2 production in enterohemorrhagic E. coli O157:H7.

By targeting quorum sensing rather than bacterial growth, the new drugs avoided stimulating the bacteria into becoming resistant. The investigators tested the compounds on 26 successive generations of both bacterial species, and found that the 26th generations were as sensitive to the antibiotics as the first. "In our lab, we call these agents everlasting antibiotics,” said senior author Dr. Vern Schramm, professor of biochemistry at Albert Einstein College of Medicine.

Related Links:

Albert Einstein College of Medicine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
All-in-One Molecular System
AIO M160
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.